ORX750: Demonstrated potential best-in-class profile for treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic ...

New York City Mayor-Elect Zohran Mamdani, who defeated Andrew Cuomo on Tuesday, showed the Democratic Party how to win with ...

ORLANDO, FLORIDA / ACCESS Newswire / October 30, 2025 / RedChip Companies will host an investor webinar with Connect Biopharma Holdings Limited (Nasdaq:CNTB) (Connect Biopharma, Connect or the Company ...

Responsible for Corporate Development, Investor Relations, Government Affairs –REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- ...

Get Q3 2025 insights on Inuvo’s earnings, AI-driven strategy, client growth, and new leadership—plus outlook for 2025 and a major class action payout.

In patients with advanced chronic kidney disease (CKD) and diabetes, treatment with rilparencel resulted in statistically significant and clinically meaningful slowing of CKD progressionBilateral ...

The reduction of health inequalities has been a priority of researchers, decision-makers and practitioners for many years.

Spinogenix received FDA authorization earlier this year for an Expanded Access Program, providing access to 200 ALS individuals ineligible for clinical trials in the United States. SPG302 has also ...

R&D Expenses: Research and development expenses for the quarter ended September 30, 2025, were $9.4 million, compared to $9.7 million for the quarter ended September 30, 2024. The expenses were ...

Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced ...

Detailed price information for Solid Biosciences Inc (SLDB-Q) from The Globe and Mail including charting and trades.

Background Hospital incident reporting and patient concerns systems are widely used to detect and respond to patient harm.